Tim Smith

These findings highlight the potential for JAKi use in alopecia areata in terms of associated neuroimmune dysregulation and comorbidities.

These data compare the characteristics and trends of anaphylaxis caused by goat and sheep’s milk allergies with those of cow’s milk and peanut allergy.

This multinational, retrospective study highlights the effect of omalizumab on chronic urticaria among patients at multiple urticaria care centers.

These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

Notable psychosocial and occupational burdens, as well as impairments to emotional well-being, were seen among caregivers of adolescents with alopecia.

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

The asthma-related emergency department visits highlighted here, following the Canadian wildfires near Ontario, were attributed to smoke inhalation.

These data suggest that heart health, as determined by the LC9 assessment, is positively correlated with pulmonary health.

This analysis highlighted the cardiovascular safety of systemic psoriasis drugs using a prospective cohort trial design.

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.

This analysis suggests intake of riboflavin, also known as vitamin B2, shows an association with patients’ risk of developing psoriasis.

In this analysis, investigators highlight the efficacy and safety of azathioprine as a monotherapy for those with recalcitrant and severe alopecia areata.

These results highlight the association between nail psoriasis and various factors such as male sex and smoking.

In this analysis, investigators highlighted both the efficacy and safety regardless of previous utilization of biologic therapies.

This analysis was a single-center retrospective cohort study, with investigators highlighting an underrecognized alopecia pattern.

This announcement by Q32 Bio Inc. highlights the Fast Track designation by the FDA granted to bempikibart (ADX-914) for alopecia areata.

These data were the conclusion of a case series highlighting the experiences and responses of African American patients with alopecia areata who utilize JAK inhibitors.

This FDA approval makes pz-cel the first single application therapy to receive FDA approval for recessive dystrophic epidermolysis bullosa.

These findings point to a need for evidence-based digital health information access to counter misinformation regarding androgenetic alopecia.

In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.

These data point to the necessity of incorporating disease burden in patient interactions and decision making for those under the age of 18 years.

These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

These data highlight the risk level among certain patients with psoriasis of excessive sun exposure, associated commonly with tanning.

In these findings, the FamilyPso tool was validated for assessing psoriasis burdens on family members in multiple countries.

This study highlights the different sex-related disparities as well as those among older adults with atopic dermatitis.

This discrete choice experiment analysis provides improved understanding of the priorities of patients using teledermatology for psoriasis.

These real-world findings on upadacitinib for atopic dermatitis highlight the drug’s efficacy and survival data among Australian patients.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.